文献速递神经PETCTMR

18F-FSPG PET/CT 显像系统 xC- 转运体活性在原发性与转移性脑肿瘤患者中的应用

18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors.
PubMed 文献 · Radiology · 2022-02-22

前瞻性单中心研究纳入26例原发性脑肿瘤(17例)或脑转移瘤(9例)患者共48个病灶,评估18F-FSPG PET/CT 对颅内恶性肿瘤的识别价值。18F-FSPG PET/CT 可识别全部48个病灶,全脑PET图像肿瘤/本底比值为26.6±24.9。在原发性脑肿瘤组,流入速率常数Ki和最大标准化摄取值相对变化鉴别病灶结局的预测准确率分别为89%和81%。

要点

  • 18F-FSPG PET/CT 可识别全部48个颅内病灶,全脑PET图像肿瘤/本底比值达26.6±24.9。
  • 在原发性脑肿瘤组,Ki相对变化预测病灶结局的准确率为89%,SUVmax相对变化为81%。
  • 原发性脑肿瘤组中好转与不良结局病灶的18F-FSPG摄取曲线差异有统计学意义(P < .05),脑转移瘤组则无。

核心结论

  • 18F-FSPG PET/CT 能以高肿瘤/本底比值检出原发性脑肿瘤和脑转移瘤;多时间点PET的18F-FSPG摄取相对变化似乎有助于预测病灶结局。

研究设计与样本

  • 前瞻性单中心研究(2014年11月至2016年3月,ClinicalTrials.gov 注册号 NCT02370563),纳入26例患者(平均年龄54岁±12,17名男性,共48个病灶),其中原发性脑肿瘤17例、脑转移瘤9例。

关键影像表现/征象

  • 18F-FSPG PET/CT 帮助识别全部48个脑病灶。
  • 全身PET时间点全脑PET图像的平均肿瘤/本底比值为26.6±24.9(范围2.6-150.3)。
  • 在行18F-FDG PET 的病例中,18F-FSPG 可显示非18F-FDG摄取病灶或更好地区分病灶与周围组织。

诊断标准与关键数值

  • 在原发性脑肿瘤患者中,流入速率常数Ki相对变化鉴别不良与良好病灶结局的预测准确率为89%。
  • 在原发性脑肿瘤患者中,最大标准化摄取值相对变化鉴别不良与良好病灶结局的预测准确率为81%。
  • 原发性脑肿瘤组中良好与不良结局病灶的18F-FSPG摄取曲线差异有统计学意义(P < .05),脑转移瘤组无此差异。

临床应用与阅片要点

  • 18F-FSPG PET/CT 可用于颅内病灶的检出,全脑PET图像肿瘤/本底比值高。
  • 多时间点18F-FSPG PET 的摄取相对变化似乎有助于预测原发性脑肿瘤的病灶结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC- cotransporter, which is overexpressed in various tumors. Purpose To assess the role of 18F-FSPG PET/CT in intracranial malignancies. Materials and Methods Twenty-six patients (mean age, 54 years ± 12; 17 men; 48 total lesions) with primary brain tumors (n = 17) or brain metastases (n = 9) were enrolled in this prospective, single-center study (ClinicalTrials.gov identifier: NCT02370563) between November 2014 and March 2016. A 30-minute dynamic brain 18F-FSPG PET/CT scan and a static whole-body (WB) 18F-FSPG PET/CT scan at 60-75 minutes were acquired. Moreover, all participants underwent MRI, and four participants underwent fluorine 18 (18F) fluorodeoxyglucose (FDG) PET imaging. PET parameters and their relative changes were obtained for all lesions. Kinetic modeling was used to estimate the 18F-FSPG tumor rate constants using the dynamic and dynamic plus WB PET data. Imaging parameters were correlated to lesion outcomes, as determined with follow-up MRI and/or pathologic examination. The Mann-Whitney U test or Student t test was used for group mean comparisons. Receiver operating characteristic curve analysis was used for performance comparison of different decision measures. Results 18F-FSPG PET/CT helped identify all 48 brain lesions. The mean tumor-to-background ratio (TBR) on the whole-brain PET images at the WB time point was 26.6 ± 24.9 (range: 2.6-150.3). When 18F-FDG PET was performed, 18F-FSPG permitted visualization of non-18F-FDG-avid lesions or allowed better lesion differentiation from surrounding tissues. In participants with primary brain tumors, the predictive accuracy of the relative changes in influx rate constant Ki and maximum standardized uptake value to discriminate between poor and good lesion outcomes were 89% and 81%, respectively. There were significant differences in the 18F-FSPG uptake curves of lesions with good versus poor outcomes in the primary brain tumor group (P < .05) but not in the brain metastases group. Conclusion PET/CT imaging with (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) helped detect primary brain tumors and brain metastases with a high tumor-to-background ratio. Relative changes in 18F-FSPG uptake with multi-time-point PET appear to be helpful in predicting lesion outcomes. Clinical trial registration no. NCT02370563 © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Wardak, Sonni, Fan, et al. 18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. Radiology. 2022. PMID: 35191738. doi:10.1148/radiol.203296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。